COMMUNIQUÉS West-GlobeNewswire

Winstrol Steroid: Benefits, Side Effects, Results & Buy Winstrol Pills Alternatives From CrazyBulk

28/03/2025 - 09:16

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for many. However, achieving substantial muscle gains is far from instantaneous. Merely [...]

Ligandrol (LGD-4033) SARMs: Benefits, Results & Buy Ligandrol Pills Alternatives From CrazyBulk

28/03/2025 - 09:16

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- A significant portion of the populace leads lifestyles that compromise both cognitive and physical functionality. Prioritizing a healthy lifestyle is paramount for optimal [...]

ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!

28/03/2025 - 08:11

TALLMADGE, Ohio, March 28, 2025 (GLOBE NEWSWIRE) -- ProvaDent is precisely fabricated to support oral health by promoting a balanced oral microbiome. It works to encourage the growth of beneficial bacteria while [...]

Pharming Group to participate in April investor conferences

28/03/2025 - 08:00

Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month [...]

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

28/03/2025 - 07:00

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a [...]

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

28/03/2025 - 07:00

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated [...]

Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO

28/03/2025 - 07:00

Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Cette approbation fait suite à celle obtenue récemment dans l’Union européenne, en Chine et aux États-Unis et repose sur [...]

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

28/03/2025 - 07:00

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, 2025 (GLOBE [...]

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

28/03/2025 - 03:30

Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial [...]

DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la...

28/03/2025 - 03:30

Châtillon, France, le 28 mars (3h30 CET) 2025 DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt [...]

VitalHub Reports Fourth Quarter and Annual 2024 Results

27/03/2025 - 23:29

Annual Recurring Revenue (ARR) ⁽¹⁻²⁾ up 59% YoY to $71.1 million Total Revenue up 51% YoY to $20.6 million Adjusted EBITDA ⁽²⁾ up 27% YoY to $5.0 million TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “ [...]

Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results

27/03/2025 - 21:55

2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- [...]

Beta Bionics Announces Board Appointment of Gerard Michel

27/03/2025 - 21:45

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as [...]

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

27/03/2025 - 21:30

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative [...]

Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025

27/03/2025 - 21:30

NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

27/03/2025 - 21:30

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter [...]

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

27/03/2025 - 21:30

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday [...]

Teva Releases Q1 2025 Aide Memoire

27/03/2025 - 21:30

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 [...]

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

27/03/2025 - 21:15

Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed A preliminary review of survival data showed [...]